Records containing: IC-MPGN
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-22A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
-
CLINICAL_TRIALS study record update · 2026-04-22A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
-
CLINICAL_TRIALS study record update · 2026-04-02An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
-
CLINICAL_TRIALS study record update · 2026-04-01A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
-
CLINICAL_TRIALS study record update · 2025-11-06US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-08-06A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
-
CLINICAL_TRIALS study record update · 2025-02-07An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
-
CLINICAL_TRIALS study record update · 2025-01-22A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SGB-9768 in Patients with Primary IgA Nephropathy, C3 Glomerulopathy, and Immune Complex-mediated Membranoproliferative Glomerulonephritis.
-
CLINICAL_TRIALS study record update · 2022-08-11An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471
-
CLINICAL_TRIALS study record update · 2021-11-26Sub-project of the Clinical Protocol ACH471-205 "An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471"